MedPath

Contrast Enhanced Ultrasound and Urine Mass Spectometry in Patients with Hepatocellular Adenoma

Completed
Conditions
Liver adenoma
10019654
10019813
Registration Number
NL-OMON36784
Lead Sponsor
Erasmus MC, Universitair Medisch Centrum Rotterdam
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
78
Inclusion Criteria

Persons 18 years and older, discharged from follow-up of the Erasmus MC with the diagnosis or probable diagnosis of hepatocellular adenoma. Informed consent must be signed.

Exclusion Criteria

Persons under 18 years.

Study & Design

Study Type
Observational invasive
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
<p>What is the sensitivity of CEUS with SonoVue compared to diagnostic modalities<br /><br>conducted in the past (radiology, histology)? </p><br>
Secondary Outcome Measures
NameTimeMethod
<p>What is the behavior of hepatocellular adenoma during and after menopause?<br /><br>Is it possible to classify hepatocellular adenoma, according to the subgroups<br /><br>of the Bordeaux group, based on contrast ultrasonography?<br /><br>Are there specific biomarkers (natural peptides and metabolites) in urine that<br /><br>can demonstrate hepatocellular adenoma?<br /><br>What is the quality of life of patients with hepatocellular adenoma?<br /><br>1. with certainty of hepatocellular adenoma (> 6 months ago)<br /><br>2. who are in a diagnostic process for hepatocellular adenoma</p><br>
© Copyright 2025. All Rights Reserved by MedPath